Business
Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
Vancouver, Canada, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (PCT) as part of its ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC) ("SciSparc"), a speci
About this update from Clearmind Medicine Inc.
[{"type":"image","alt":"Clearmind Medicine Inc.","displaySize":"","headline":null,"caption":"Clearmind Medicine Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":46,"url":"https://media.zenfs.com/en/globenewswire.com/e18eb6f6a6c8d81f644b0fcdb3ee6405"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LYbHRS3_v8ob5T6A1Lc.4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY0O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/e18eb6f6a6c8d81f644b0fcdb3ee6405","width":300,"height":46}},"lazy":false},{"type":"text","content":"Vancouver, Canada, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (PCT) as part of its ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC) ("SciSparc"), a specialty clinical-stage pharmaceutical company developing therapies for central nervous system disorders.","length":621,"tagName":"p"},{"type":"text","content":"The patent application published under the European Patent Office covers an innovative combination therapy of Clearmind’s proprietary 5-methoxy-2-aminoindane (MEAI) and SciSparc’s Palmitoylethanolamide (PEA) for the treatment of metabolic syndrome and obesity.","length":260,"tagName":"p"},{"type":"text","content":"Metabolic syndrome, characterized by conditions such as high blood pressure, high blood sugar, excess abdominal fat, and elevated cholesterol levels, affects up to one-third of U.S. adults and increases the risk of heart disease, stroke, obesity and type 2 diabetes. This proprietary combination therapy leverages MEAI’s unique pharmacological profile alongside PEA’s anti-inflammatory and neuroprotective properties to offer a potential safe and effective treatment for these widespread health challenges.","length":506,"tagName":"p"},{"type":"text","content":"This patent publication marks a significant milestone in the Clearmind-SciSparc collaboration, which has resulted in the filing of 13 patent families, across multiple jurisdictions, such as the United States, Europe, and China. The collaboration focuses on developing innovative ...